82

Hozirgi vaqtda dunyoning aksariyat mamlakatlarida metabolik xavf omillariga katta ahamiyat berilmoqda, chunki metabolik sindrom (MS)
rivojlanishining kuchayishi tendensiyasi mavjud. Arterial gipertenziya (AG) metabolik kasalliklar bilan og'rigan bemorlar orasida eng ko`p
tarqalgan xavf omili bo'lib, yurak-qon tomir kasalliklari asoratlari xavfini oshiradi. Qorin bo'shlig'idagi semirish, arterial gipertenziya (AG),
dislipidemiya va insulin qarshiligi kabi quyidagi xavf omillarini birlashtirgan metabolik sindrom yurak-qon tomir kasalliklari va falokatlarning
bashoratchisi hisoblanadi. Simptomlar majmuasining 17 ta yurak-qon tomir kasalliklarini (YQTK) rivojlanish ehtimolini oshiradigan mexanizmlar
faqat qisman tushuniladi. Buning sabablaridan biri elastiklikning yo'qolishi va endotelial disfunktsiyaning (ED) rivojlanishi bilan namoyon
bo'ladigan katta tomirlardagi erta o'zgarishlar bo'lishi mumkin. Shunday qilib, metabolik sindrom (MS) yurak-qon tomir kasalliklarining rivojlanishi
uchun eng muhim xavf omillarining kombinatsiyasi hisoblanadi: buzilgan uglevod almashinuvi, semizlik, dislipidemiya va arterial gipertenziya
(AG). Metabolik sindromning haqiqiy sindrom majmuasimi yoki alohida-alohida emas, balki birgalikda ko'proq uchraydigan xavf omillarining
kombinatsiyasi ekanligi haqida hali ham kelishmovchiliklar mavjud.

  • Количество прочтений82
  • Дата публикации15-12-2021
  • Язык статьиO'zbek
  • Страницы18-21
Ўзбек

Hozirgi vaqtda dunyoning aksariyat mamlakatlarida metabolik xavf omillariga katta ahamiyat berilmoqda, chunki metabolik sindrom (MS)
rivojlanishining kuchayishi tendensiyasi mavjud. Arterial gipertenziya (AG) metabolik kasalliklar bilan og'rigan bemorlar orasida eng ko`p
tarqalgan xavf omili bo'lib, yurak-qon tomir kasalliklari asoratlari xavfini oshiradi. Qorin bo'shlig'idagi semirish, arterial gipertenziya (AG),
dislipidemiya va insulin qarshiligi kabi quyidagi xavf omillarini birlashtirgan metabolik sindrom yurak-qon tomir kasalliklari va falokatlarning
bashoratchisi hisoblanadi. Simptomlar majmuasining 17 ta yurak-qon tomir kasalliklarini (YQTK) rivojlanish ehtimolini oshiradigan mexanizmlar
faqat qisman tushuniladi. Buning sabablaridan biri elastiklikning yo'qolishi va endotelial disfunktsiyaning (ED) rivojlanishi bilan namoyon
bo'ladigan katta tomirlardagi erta o'zgarishlar bo'lishi mumkin. Shunday qilib, metabolik sindrom (MS) yurak-qon tomir kasalliklarining rivojlanishi
uchun eng muhim xavf omillarining kombinatsiyasi hisoblanadi: buzilgan uglevod almashinuvi, semizlik, dislipidemiya va arterial gipertenziya
(AG). Metabolik sindromning haqiqiy sindrom majmuasimi yoki alohida-alohida emas, balki birgalikda ko'proq uchraydigan xavf omillarining
kombinatsiyasi ekanligi haqida hali ham kelishmovchiliklar mavjud.

№ Название ссылки
1 1. Nasirova Z.A., Tashkenbayeva E.N., Nasirova D.A. Psixosomatik holatlarning yurak qon tomir kasalliklari bilan aloqasi //cardio. – 2020. – Т. 1. – №. 3. 2. Nasirova Z.A., Tashkenbayeva E.N. Yurak ishemik kasalliklarig depressiv sindrom va yalig`langan sitokenli genlarnin ta’siri //axborotnomasi. – С. 53. 3. Tashkenbayeva E.N., Nasirova Z.A., Mirzayev R.Z. Surunkali ishemik yurak kasalligining diagnostika usullari va ularni davolash usullariga qarab tabaqalanishi//Kardiorespirator tadqiqotlar jurnali – 2020. – Т. 1. – №. 3. 4. Ellamonov S.N. va boshqalar. 2-tip qandli diabet bilan kasallangan bemorlarda arterial gipertenziya kasalligining rivojlanishining omillari// Kardiorespirator tadqiqotlar jurnali. – 2021. – Т. 2. – №. 2. 5. Oelze M., Glutathione peroxidase-1 deficiency potentiates disregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. / M. Oelze, S. Kroller-Schon, S. Steven et al. // Hypertension. ― 2014 ― Vol. 63 ― P.390-396 6. O. Brien, E. Unmasking hypertension/ E. O,Brien // Hypertension. ― 2005. ― Vol. 45, № 4. ― P. 481-482. 218. O ,Rourke, M.F Guidelines on guidelines: focus on isolated systolic hypertension in youth / M.F. O,Rourke, A. Adji // J. Hypertens. ― 2013. ― Vol. 31. ― Р. 649- 654. 7. Palatini, P. Arterial stiffnes, central hemodynamics, and cardiovascular risk in hypertension / P. Palatini, E. Casiglia, G. Gasowski // Vasc. Health Risk Manag. ― 2011. ― №7. ― Р. 725-39. 8. Piepoli, M.F. European Guidelines on cardiovascular disease prevention in clinical practice / M.F. Piepoli, A.W. Hoes, S. Agewall, C. Albus, C. Brotons, A.L. Catapano, M.T. Cooney, U. Corrà, B. Cosyns, C. Deaton, I. Graham, M.S. Hall, F.D.R. Hobbs, M.L. Løchen, H. Löllgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D.J. Richter, N. Sattar, Y. Smulders, M. Tiberi, H.B. van der Worp, I. van Dis, W.M.M.G. Verschuren // European Heart Journal. ― 2016. ― № 37. ― P. 2315-2381. 9. Ragot S. Prevalence and management of hypertensive patients in clinical practice: Cross-sectional registry in five countries outside the European Union Blood Press. / S. Ragot, M. Beneteau, F. Guillou-Bonnici et al. // Taylor & Francis. ― 2016. ― Vol. 25, № 2. ― P. 104- 116. 10. Terawaki, H. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study / H. Terawaki, M. Nakayama, E. Miyazawa, et al. // Clinical and Exp Nephrol. ― 2013. ― № 17(4). ― P. 549-53. 11. Tessari, P. Roles of insulin, age, and assimetric dimethylarginine, on nitric oxide synthesis in vivo / P. Tessari, D. Cecchet, C. Artusi et al. // Diabetes. ― 2013. ― № 62 (10). ― P. 2699-2708.
В ожидании